KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Operations (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Cash from Operations for 16 consecutive years, with 999000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 1507.04% year-over-year to 999000.0, compared with a TTM value of 2096000.0 through Sep 2025, up 155.06%, and an annual FY2024 reading of 1170000.0, up 105.07% over the prior year.
  • Cash from Operations was 999000.0 for Q3 2025 at TherapeuticsMD, up from 381000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 48002000.0 in Q4 2021 and bottomed at 38380000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 3452947.37, with a median of 229000.0 recorded in 2024.
  • The sharpest move saw Cash from Operations crashed 134.03% in 2023, then soared 1507.04% in 2025.
  • Year by year, Cash from Operations stood at 48002000.0 in 2021, then tumbled by 37.01% to 30236000.0 in 2022, then tumbled by 116.4% to 4960000.0 in 2023, then soared by 100.34% to 17000.0 in 2024, then skyrocketed by 5776.47% to 999000.0 in 2025.
  • Business Quant data shows Cash from Operations for TXMD at 999000.0 in Q3 2025, 381000.0 in Q2 2025, and 699000.0 in Q1 2025.